Results 101 to 110 of about 86,629 (276)

Data from Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells

, 2023
Stephanie Markovina, Natalie S. Callander, Shelby L. O’Connor, Jihoon Kim, Jae Werndli, Martha Raschko, Catherine P. Leith, Brad S. Kahl, KyungMann Kim, Shigeki Miyamoto   +9 more
openalex   +1 more source

Table S1: IC50 (nM) for M cells deleted PSMC subunits treated with BTZ from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma [PDF]

, 2023
Chang‐Xin Shi, K. Martin Kortüm, Yuan Xiao Zhu, Laura A. Bruins, Patrick Jedlowski, Patrick G. Votruba, Moulun Luo, Robert A. Stewart, Jonathan M. Ahmann, Esteban Braggio, A. Keith Stewart   +10 more
openalex   +1 more source

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment

European Journal of Haematology, EarlyView.
ABSTRACT Background Severe renal insufficiency requiring dialysis in newly diagnosed multiple myeloma (NDMM) patients has been independently associated with poor survival outcomes. However, there is a paucity of data on factors predicting renal recovery and survival outcomes of these patients.
Rintu Sharma, Eshetu G. Atenafu, Esther Masih‐Khan, Harjot Vohra, Sita Bhella, Christine Chen, Vishal Kukreti, Guido Lancman, Anca Prica, A. Keith Stewart, Rodger Tiedemann, Suzanne Trudel, Chloe Yang, Donna Reece   +13 more
wiley   +1 more source

Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma

Frontiers in Oncology, 2019
Multiple myeloma (MM) drug resistance highlights a need for alternative therapeutic strategies. In this study, we show that CASIN, a selective inhibitor of cell division cycle 42 (Cdc42) GTPase, inhibited proliferation and survival of melphalan ...
Phuong Nguyen, Phuong Nguyen, Jayati Chakrabarti, Jayati Chakrabarti, Yuan Li, Yuan Li, Khalid W. Kalim, Khalid W. Kalim, Mengnan Zhang, Lin Zhang, Yi Zheng, Yi Zheng, Fukun Guo, Fukun Guo   +13 more
doaj   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, EarlyView.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Determining cellular and biochemical function of a novel adhesion molecule in kidneys. [PDF]

, 2016
Acute kidney injury is an abrupt loss of kidney function that develops in short time with limited effective treatments other than kidney transplantation. We have identified TMIGD1 (Transmembrane immuno- globulin domain 1) as a novel receptor expressed in
Arafa, Emad
core   +1 more source

Extramedullary Disease—Achilles Heel in Myeloma?

American Journal of Hematology, Volume 101, Issue 3, Page 521-536, March 2026.
ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar, Joshua Richter, Saad Z. Usmani, Yael C. Cohen, Jing Christine Ye, María‐Victoria Mateos, Vania Hungria, Elena Zamagni   +7 more
wiley   +1 more source

Spatial sequestration of activated-caspase 3 in aggresomes mediates resistance of neuroblastoma cell to bortezomib treatment

Scientific Reports
Neuroblastoma (NB) is the most common pediatric tumor and is currently treated by several types of therapies including chemotherapies, such as bortezomib treatment.
Kévin Berthenet, Eliézer Aïmontché, Sara El Mrini, Johan Brière, Nathalie Pion, Isabelle Iacono, Stéphanie Brejon, Karine Monier, Frédéric Catez, Gabriel Ichim, Valérie Combaret, Hichem C. Mertani, Jean-Jacques Diaz, Marie Alexandra Albaret   +13 more
doaj   +1 more source

Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.

PLoS ONE, 2013
CK2 is a pivotal pro-survival protein kinase in multiple myeloma that may likely impinge on bortezomib-regulated cellular pathways. In the present study, we investigated CK2 expression in multiple myeloma and mantle cell lymphoma, two bortezomib ...
Sabrina Manni, Alessandra Brancalion, Elisa Mandato, Laura Quotti Tubi, Anna Colpo, Marco Pizzi, Rocco Cappellesso, Fortunato Zaffino, Speranza Antonia Di Maggio, Anna Cabrelle, Filippo Marino, Renato Zambello, Livio Trentin, Fausto Adami, Carmela Gurrieri, Gianpietro Semenzato, Francesco Piazza   +16 more
doaj   +1 more source

Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745–4753. [PDF]

, 2012

openalex   +1 more source